Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dordaviprone - Chimerix

X
Drug Profile

Dordaviprone - Chimerix

Alternative Names: NSC-350625; ONC 201; OP-10; TIC-10; TRAIL-inducing compound 10

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncoceutics
  • Developer Brown University; Case Comprehensive Cancer Center; Chimerix; Fox Chase Cancer Center; Kazia Therapeutics; Ohara Pharmaceutical; Oncoceutics; Rutgers; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Imidazoles; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Endopeptidase Clp stimulants; TNF-related apoptosis-inducing ligand receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioma
  • Phase II Breast cancer; Endometrial cancer; Glioblastoma; Neuroendocrine tumours
  • Phase I/II Acute myeloid leukaemia; Colorectal cancer; Gallbladder cancer; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Cancer; Renal failure
  • Preclinical Adenocarcinoma; Liver cancer; Ovarian cancer; Prostate cancer; Sarcoma; Small cell lung cancer; Thyroid cancer
  • No development reported Mantle-cell lymphoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 May 2024 Chimerix plans to file regulatory application for Dordaviprone in Australia around year end
  • 01 May 2024 Chimerix plans to launch Dordaviprone in 2026
  • 16 Jan 2024 Fox Chase Cancer Center and Oncoceutics terminated a phase II trial for Endometrial cancer (Metastatic disease, Recurrent, Second-line therapy or greater) (PO)(NCT03099499)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top